Publications
5600 Results
- Journal / Conference
- San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), TIPs poster, abst.# OT1-03-11;
- Year
- 2015
- Research Committee(s)
- Breast
- Study Number(s)
- S1207
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140)
- Journal / Conference
- Journal of Clinical Oncology, Dec 1;33(34):4066-4076
- Year
- 2015
- Research Committee(s)
- Melanoma
- PMID
- PMID26351350
- PMC
- PMC4669592
- Study Number(s)
- E4697
A randomized placebo-controlled phase III trial of yeast derived GM-CSF vs peptide vaccination vs GM-CSF plus peptide vaccination vs placebo in patients with "no evidence of disease" after complete surgical resection of “locally advanced" and/or stage IV melanoma: a trial of the ECOG- ACRIN cancer research group (E4697)
- Journal / Conference
- European Multidisciplinary Meeting on Urological Cancers (EMUC)(Nov 12-15, 2015, Barcelona, Spain), oral presentation; abst O6
- Year
- 2015
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0421
SWOG 0421: Impact of circulating markers of bone metabolism on overall survival in men with metastatic castration resistant prostate cancer (CRPC)
- Journal / Conference
- Haematologica Oct;100(10):e409-11
- Year
- 2015
- Research Committee(s)
- Leukemia
- PMID
- PMID26160876
- PMC
- PMC4591777
- Study Number(s)
- S0106
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- Journal / Conference
- San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abst. S2-05;
- Year
- 2015
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/C40603
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)
- Journal / Conference
- Blood 126(23):796; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL),oral presentation;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0805
Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60
- Journal / Conference
- Blood 126(23):25; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777
- Journal / Conference
- Blood 126(23):518; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1106
Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma
- Journal / Conference
- Blood 126(23):578; American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral;
- Year
- 2015
- Research Committee(s)
- Lymphoma
Results of US intergroup trial of response-adapted chemotherapy based on PET for non-bulky stage I and II hodgkin lymphoma (HL) (CALGB/Alliance 50604) (http://www.bloodjournal.org/content/126/23/578)
- Journal / Conference
- Blood 126(23):3803; American Society of Hematology Annual Meeting (Dec 5-8, 2015, poster;
- Year
- 2015
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0919